Clinical trials: Healthy Male/Female Subjects
Healthy
Effect of BI 1356 as Single Dose on the QT Interval in Healthy Female and Male Subjects
Assessment of the effect of BI 1356 or Placebo on prolongation of the QT interval
- Trial name
- NCT02183467
- Testing
- BI 1356, low dose, BI 1356, high dose, Moxifloxacin
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Injection Site Study In Patients With Type 2 Diabetes Mellitus (T2DM) And Healthy Volunteers
This study is an open-label study in healthy volunteers and in patients with Type 2 Diabetes Mellitus to assess safety and tolerability parameters, the levels of GSK716155 in the bloodstream after a single dose given at different…
- Trial name
- NCT00394030
- Testing
- GSK716155 subcutaneous injections
- Where
- 6 sites in United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Drug-interaction Trial in Healthy Subjects With Oral Administration of Empagliflozin (BI 10773), Rifampicin and Probenecid
The objectives of the trial are to investigate the effect of concurrent administration of rifampicin and probenecid on the pharmacokinetics of empagliflozin.
- Trial name
- NCT01634100
- Testing
- Probenecid, Rifampicin, Empagliflozin
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Antidiarrheals
Bioequivalence Between a Racecadotril Capsule and Film-Coated Tablet (FCT) to Treat Diarrhea in Adults
This study is designed to assess bioequivalence between two products used for treatment of acute diarrhea.
- Trial name
- NCT01302093
- Testing
- Racecadotril Film-Coated Tablet (FCT), Racecadotril Capsule
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- McNeil AB
Rheumatoid Arthritis
AZD5672 Bioavailability Study in Healthy Male and Female Subjects
The aim of this study is to compare the blood levels achieved with a new formulation of AZD5672 to an existing formulation of AZD5672 used in previous studies
- Trial name
- NCT00871767
- Testing
- AZD5672
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy, Renal Impairment
The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics
To investigate the PK of cenerimod in participants with severe renal impairment as compared to healthy control participants.
- Trial name
- NCT05004311
- Testing
- Cenerimod
- Where
- Portugal
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Viatris Innovation GmbH
Retention, Urinary
Exploratory Study Investigating the Urinary Bladder During Intermittent Catheterization in Healthy and Spinal Cord Injured Male and Female Subjects Using an Upright MRI Scanner
This is an exploratory study investigating morphological and physiological changes of the lower urinary tract and surrounding structures during IC use in individuals with SCI, and during normal voiding and IC use in healthy…
- Trial name
- NCT07384559
- Testing
- MRI scan
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Coloplast A/S
Renal Insufficiency
Pharmacokinetics (PK) and Metabolism of FTY720 in Patients With Severe Renal Impairment and Healthy Matched Subjects.
The purpose of this study is to compare the pharmacokinetics of FTY720 and its metabolites in patients with severe renal insufficiency and in matched, healthy volunteers.
- Trial name
- NCT00731523
- Testing
- fingolimod (FTY720)
- Where
- Russia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Novartis
Healthy
Safety, Pharmacodynamic and Pharmacokinetic Effects of QAX576 in Healthy Volunteers.
This study is designed to evaluate the safety, pharmacodynamic and pharmacokinetic effects of individual escalating intravenous doses of QAX576 in healthy volunteers.
- Trial name
- NCT00417196
- Testing
- QAX576
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novartis
Renal Impairment
Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients
This is a Phase 1, Multicenter, Open-Label, Parallel Group Adaptive Pharmacokinetic Single Dose Study of ISIS 681257 Subcutaneous Injections in Male And Female Subjects with Normal and Impaired Renal Function
- Trial name
- NCT03506854
- Testing
- ISIS 681257
- Where
- 3 sites in United States, Canada
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Akcea Therapeutics
Renally Impaired Subjects
Single-dose Pharmacokinetics and Safety of Oral Lofexidine in Renally-Impaired Subjects
This is a phase 1, open-label, parallel-group, single-dose study of lofexidine in 8 adult subjects with ESRD maintained on hemodialysis (3 times per week) and 8 control subjects with normal renal function, recruited as 1:1…
- Trial name
- NCT02313103
- Testing
- lofexidine HCl
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- USWM, LLC (dba US WorldMeds)
Phase 1
Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female Subjects
The study is a monocentric, open label, phase 1 study to evaluate the pharmacokinetics, and in particular the dose proportionality of setanaxib and its metabolites after a single oral dose (400 mg, 800 mg, 1200 mg, and 1600 mg)…
- Trial name
- NCT04327089
- Testing
- Setanaxib
- Where
- France
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Calliditas Therapeutics AB
Advanced Malignancies
Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State
In this study two MGCD265 oral formulations at dose level of 100 mg are administered to healthy male and female subjects under fasting conditions.
- Trial name
- NCT01930006
- Testing
- MGCD265
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Mirati Therapeutics Inc.
Renal Impairment
A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment
The purpose of this study is to evaluate the pharmacokinetics and safety of a single dose of Inaxaplin (IXP) in participants with severe renal impairment and healthy participants with normal renal function.
- Trial name
- NCT05865171
- Testing
- IXP
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Normal Renal Function, Impaired Renal Function
Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011
The purpose of this study is to characterize the PK and safety profile of LEE011 following a single oral dose in adult subjects with various degrees of renal impairment compared to a matched group of healthy subjects with normal…
- Trial name
- NCT02431481
- Testing
- LEE011
- Where
- 4 sites in United States, Bulgaria and 2 more
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Healthy Subjects
Study of KBP-7072 in Healthy Male and Female Subjects
This is a double-blind, randomized, placebo-controlled, single and multiple IV dose study conducted in two parts. Part A (SAD) will comprise an ascending single dose, sequential group design.
- Trial name
- NCT05507463
- Testing
- KBP-7072
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- KBP Biosciences
Healthy
A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Non-fasting Conditions
To compare the rate and extent of absorption of griseofulvin from a test formulation of Griseofulvin 125 mg/5 mL Suspension versus the reference Grifulvin V® 125 mg/5 mL Suspension under fed conditions.
- Trial name
- NCT00863863
- Testing
- Griseofulvin 125 mg/5 mL Suspension, single dose, Grifulvin V® 125 mg/5 mL Suspension, single dose
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Actavis Inc.
Healthy Subjects, Plasma Concentration of Mirabegron
A Study to Evaluate Absorption, Distribution and Elimination of Mirabegron After Oral Administration to Non-elderly Healthy Chinese Subjects
The purpose of this study is to evaluate safety and absorption, distribution and elimination of mirabegron after oral administration to Chinese subjects.
- Trial name
- NCT01747564
- Testing
- YM178 (mirabegron)
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Pharmacokinetics
Fasted Bioequivalence Study of Clopidogrel Film-coated Tablets, 75 mg in 48 Healthy, Adult Male and Female Subjects.
This study was designed to compare bioequivalence of the Test Product Clopidogrel bisulfate, film-coated tablets, 75 mg (JSC Farmak, Ukraine) and Reference Product Plavix® 75 mg film-coated tablets (Sanofi Winthrop Industrie…
- Trial name
- NCT05125549
- Testing
- Сlopidogrel bisulfate film-coated tablets, 75 mg (JSC Farmak, Ukraine), Plavix® 75 mg film-coated tablets (Sanofi Winthrop Industrie, France)
- Where
- Ukraine
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Joint Stock Company "Farmak"
Kidney Failure, Chronic
Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects
A phase I, open-label study comparing the pharmacokinetics, pharmacodynamics, safety and tolerability of ticagrelor in hemodialysis patients to healthy subjects with normal renal function.
- Trial name
- NCT02022748
- Testing
- ticagrelor
- Where
- 2 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca